KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Cash from Operations (2018 - 2025)

Castle Biosciences (CSTL) has disclosed Cash from Operations for 8 consecutive years, with 26931000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Operations rose 10.53% to 26931000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 64347000.0 through Dec 2025, down 0.8% year-over-year, with the annual reading at 64347000.0 for FY2025, 0.8% down from the prior year.
  • Cash from Operations hit 26931000.0 in Q4 2025 for Castle Biosciences, up from 22631000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 26931000.0 in Q4 2025 to a low of 25439000.0 in Q1 2023.
  • Historically, Cash from Operations has averaged 3147450.0 across 5 years, with a median of 3708500.0 in 2021.
  • Biggest five-year swings in Cash from Operations: tumbled 1346.61% in 2021 and later soared 733.86% in 2024.
  • Year by year, Cash from Operations stood at 2781000.0 in 2021, then crashed by 115.75% to 6000000.0 in 2022, then surged by 409.78% to 18587000.0 in 2023, then soared by 31.09% to 24365000.0 in 2024, then rose by 10.53% to 26931000.0 in 2025.
  • Business Quant data shows Cash from Operations for CSTL at 26931000.0 in Q4 2025, 22631000.0 in Q3 2025, and 20821000.0 in Q2 2025.